KTTA — Pasithea Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Pasithea Strengthens Scientific Advisory Board With Appointment Of Merit Cudkowicz
Brief: Camac Partners Issues Letter To Pasithea Therapeutics Stockholders
Brief: Pasithea Therapeutics to present results of tolerizing vaccine program at Prestigious International Immunotherapy Conference
Brief: Pasithea Therapeutics Announces Results Of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy In Relapsing-Remitting Model Of Multiple Sclerosis
Brief: Pasithea Therapeutics Corp Says Investor Group Urges Stockholders To Call Special Meeting
Brief: Pasithea Therapeutics Corp - Filed Its Definitive Consent Revocation Statement With U.S. SEC And Sent A Letter To Pasithea Stockholders
Brief: Pasithea Therapeutics Awarded Drug Development Research Grant
Brief: Camac Partners Llc Says Investor Group Intends To Withhold On All Of Pasithea's Sitting Directors At Upcoming Annual Meeting Of Stockholders
Brief: Pasithea Therapeutics Acquires Alpha-5 Integrin LLC
Brief: Pasithea Therapeutics Says CFO Passed Away
Brief: Pasithea Therapeutics Announces Financial And Business Results For The Fourth Quarter
Brief: Pasithea Therapeutics Announces Collaboration With The Glimpse Group
Brief: Pasithea Therapeutics Announces Plans To Open Three New Clinics In The UK
Brief: Pasithea Therapeutics Appoints Preeminent Scientist Dr. Daniel Weinberger
Brief: Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program In Multiple Sclerosis
Brief: Pasithea Therapeutics Corp Files For Potential Offering Of 17.7 Mln Shares Of Common Stock Offered By Selling Stockholders
Brief: Pasithea Therapeutics Expands Its Mobile Clinics Into Florida And Nevada
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:01 PM
U.S. STOCKS ON THE MOVE-Nordstrom, Gap, HP Inc, Chevron